GlycoMimetics, Inc. - Common Stock (GLYC)
0.2609
-0.0207 (-7.35%)
Glycomimetics Inc. is a biotechnology company focused on developing innovative therapies for serious diseases, particularly in the areas of cancer and rare blood disorders
The company specializes in creating glycomimetic drugs, which are designed to replicate the functionality of carbohydrates that play crucial roles in biological processes, including cell adhesion and interaction. By harnessing this technology, Glycomimetics aims to target and disrupt disease mechanisms, thereby improving treatment options and outcomes for patients. Their pipeline includes a range of drug candidates that are undergoing clinical trials, highlighting their commitment to advancing medical science and enhancing patient care.
Previous Close | 0.2816 |
---|---|
Open | 0.2794 |
Bid | 0.2500 |
Ask | 0.2590 |
Day's Range | 0.2529 - 0.2884 |
52 Week Range | 0.1406 - 3.180 |
Volume | 469,338 |
Market Cap | 16.82M |
PE Ratio (TTM) | -0.4422 |
EPS (TTM) | -0.6 |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 3,361,985 |
News & Press Releases

Let's have a look at what is happening on the US markets on Wednesday. Below you can find the stocks with an unusual volume in today's session.
Via Chartmill · February 19, 2025

The US market session of Tuesday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.
Via Chartmill · February 18, 2025

From merger updates to earnings surprises, these healthcare stocks saw the biggest spike in Stocktwits chatter.
Via Stocktwits · February 17, 2025

Via Benzinga · February 18, 2025

Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.
Via Chartmill · February 17, 2025

Via Benzinga · February 18, 2025

As the regular session of the US market on Friday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
Via Chartmill · February 14, 2025

GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that data from multiple clinical trials studying uproleselan in patients with acute myeloid leukemia (AML) have been accepted for presentation at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in San Diego, California, on December 7-10, 2024.
By GlycoMimetics, Inc. · Via Business Wire · November 6, 2024

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of GlycoMimetics, Inc. (NasdaqGM: GLYC) and Crescent Biopharma, Inc. Pursuant to the terms of the agreement, shareholders of GlycoMimetics will own approximately 3.1% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger is fair to GlycoMimetics shareholders.
By Kahn Swick & Foti, LLC · Via Business Wire · October 31, 2024

Via Benzinga · October 30, 2024

Via Benzinga · October 30, 2024

GlycoMimetics, Inc. (NASDAQGLYC) shares are moving higher on Tuesday after the company announced it will merge with Crescent Biopharma. The company also said it secured $200 million in funding to advance its oncology pipeline.
Via Benzinga · October 29, 2024

Via Benzinga · October 29, 2024

Via Benzinga · October 29, 2024

Via Benzinga · October 29, 2024

NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
By Halper Sadeh LLC · Via GlobeNewswire · October 29, 2024

BALA CYNWYD, Pa., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
By Brodsky & Smith LLC · Via GlobeNewswire · October 29, 2024

Ademi LLP is investigating GlycoMimetics (NASDAQGLYC) for possible breaches of fiduciary duty and other violations of law in its transaction with Crescent.
By Ademi LLP · Via Business Wire · October 29, 2024

Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of GlycoMimetics, Inc. (NASDAQGLYC) and Crescent Biopharma, Inc. is fair to GlycoMimetics shareholders. Upon closing of the proposed transaction, GlycoMimetics stockholders are expected to own approximately 3.1% of the combined company.
By Halper Sadeh LLC · Via Business Wire · October 29, 2024

GlycoMimetics, Inc. (NASDAQGLYC) announced today it has entered into an acquisition agreement with Crescent Biopharma, Inc. (“Crescent”), a privately held biotechnology company advancing a pipeline of oncology therapeutics designed to treat solid tumors. Upon completion of the transaction, the Company plans to operate under the name Crescent Biopharma, Inc.
By GlycoMimetics, Inc. · Via Business Wire · October 29, 2024

GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced the Phase 2 analysis of the adaptive Phase 2/3 study of uproleselan being conducted by the National Cancer Institute (NCI) and the Alliance for Clinical Trials in Oncology in adults with newly diagnosed acute myeloid leukemia (AML) who are 60 years or older and fit for intensive chemotherapy. This study did not show a statistically significant improvement in event free survival (EFS) for patients receiving uproleselan in combination with 7+3 chemotherapy versus chemotherapy alone.
By GlycoMimetics, Inc. · Via Business Wire · October 29, 2024

GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced the initiation of a strategic review and corporate restructuring plan. GlycoMimetics has engaged Lucid Capital Markets to act as a strategic advisor in the process.
By GlycoMimetics, Inc. · Via Business Wire · July 25, 2024

Biotech stocks can be extremely challenging because it takes a long time to bring a therapy to market. Here are some biotech stocks to sell.
Via InvestorPlace · July 22, 2024